Candriam S.C.A. Grows Stock Holdings in United Therapeutics Corporation $UTHR

Candriam S.C.A. grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 48.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,387 shares of the biotechnology company’s stock after purchasing an additional 40,176 shares during the quarter. Candriam S.C.A. owned approximately 0.29% of United Therapeutics worth $51,725,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of UTHR. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after buying an additional 96 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 498,714 shares of company stock worth $240,366,488 over the last 90 days. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Trading Up 1.3%

NASDAQ UTHR opened at $485.36 on Monday. The company has a market cap of $20.90 billion, a PE ratio of 18.39, a PEG ratio of 2.58 and a beta of 0.85. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The stock’s 50-day moving average price is $486.75 and its two-hundred day moving average price is $428.33.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group lifted their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.